- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06368414
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia (AsterA)
April 11, 2024 updated by: Korean Society of Hematology
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia in Combination With Asciminib and Tyrosine Kinase Inhibitors
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
We expect that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs.
Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation.
Study Type
Interventional
Enrollment (Estimated)
69
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hawk Kim
- Phone Number: 82-10-8533-8019
- Email: ksh.cml.wp@gmail.com
Study Contact Backup
- Name: Eunju Park
- Phone Number: 82-10-8533-8019
- Email: ksh.cmlwp.cra1@gmail.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 19 year or older
- CP-CML patients who are taking current TKIs (imatinib, nilotinib or dasatinib) for 5 years or more
- Patients who have failed maintaining MR3.0 after 1 or more cessation trial of TKIs.
- Patients who regained MR3.0 or deeper molecular response by TKIs retrial after TKI cessation failure at the time of screening
- Taking TKIs over 12 weeks for the retrial of TKIs after TKI cessation failure
- Patients who agree with stopping asciminib and TKIs after maintaining 23 year-duration of MR4.5
Adequate end organ function as defined by:
- Total bilirubin (TBL) < 3 x upper limit of normal (ULN); patients with Gilbert's syndrome may only be included if TBL ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN
- Creatinine clearance (ClCr) ≥ 30 mL/min as calculated using Cockcroft-Gault formula
- Serum lipase ≤ 1.5 x ULN. For serum lipase > ULN - ≤ 1.5 x ULN, value must be considered not clinically significant and not associated with risk factors for acute pancreatitis
- Patients who can sign the informed consent of their own free will
Exclusion Criteria:
- Patients who experienced grade 3 or higher adverse events with TKIs (imatinib, dasatinib, and nilotinib).
- Patients who are receiving any other investigational agents.
- Patients who currently have uncontrolled infections
- Patients who previously received Chimeric antigen receptor T-cell (CAR-T cell) therapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) or biologic therapy.
- Patients with clinically significant cardiovascular disease or gastrointestinal dysfunction.
- Patients who have a history of thromboembolic episodes within 3 months prior to the study enrollment.
- Patients with active hepatitis B or C with uncontrolled disease activity.
- Patients who have active malignancies requiring treatment other than CML.
- Patients with any severe and/or uncontrolled medical conditions or other conditions that could adversely impact on patients' ability to participate in the study.
- Patients with psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with asciminib and TKIs, breastfeeding should be discontinued if the mother is treated with asciminib and TKIs.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Asciminib arm
|
that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs.
Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MR3.0 or less by 1 year
Time Frame: by 1 year
|
To evaluate the cumulative incidence of sustained MR3.0 or less by 1 year of cessation of TKI and asciminib
|
by 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Hawk Kim, Korean Society of Hematology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2024
Primary Completion (Estimated)
August 31, 2028
Study Completion (Estimated)
August 31, 2028
Study Registration Dates
First Submitted
April 11, 2024
First Submitted That Met QC Criteria
April 11, 2024
First Posted (Actual)
April 16, 2024
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 11, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Chronic Disease
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Asciminib
Other Study ID Numbers
- KCMLWP-2021-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myeloid Leukemia, Chronic Phase
-
Asan Medical CenterTerminatedLeukemia, Chronic Myeloid | Myeloid Leukemia, Chronic, Chronic Phase | Myeloid Leukemia, Chronic, Accelerated PhaseKorea, Republic of
-
Newcastle UniversityBristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaboratorsCompletedMyeloid Leukemia, Chronic, Chronic PhaseUnited Kingdom
-
ChemGenex PharmaceuticalsTerminatedMyeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast PhaseUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myelogenous Leukemia - Chronic PhaseChina
-
Fundacion Espanola para la Curacion de la Leucemia...Pfizer; Roche Farma, S.ATerminatedChronic Phase-Chronic Myeloid LeukemiaSpain
-
TakedaActive, not recruitingMyeloid Leukemia, Chronic, Chronic PhaseUnited States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte Corporation; H. Jean Khoury Cure CML ConsortiumRecruitingChronic Myeloid Leukemia, Chronic Phase | Chronic Phase Chronic Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.RecruitingCML, Chronic Phase | CML, Accelerated PhaseChina
-
Gruppo Italiano Malattie EMatologiche dell'AdultoFundacion Espanola para la Curacion de la Leucemia Mieloide CronicaNot yet recruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | Chronic Myeloid Leukemia, BCR/ABL-Positive
Clinical Trials on Asciminib
-
Novartis PharmaceuticalsCompletedRenal ImpairmentGermany, Bulgaria
-
Novartis PharmaceuticalsRecruitingChronic Myelogenous Leukemia - Chronic PhaseUnited States
-
Novartis PharmaceuticalsActive, not recruitingHematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid ChronicTaiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingPhiladelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous LeukemiaUnited States
-
Medical College of WisconsinH. Jean Khoury Cure CML ConsortiumRecruitingChronic Phase Chronic Myelogenous LeukemiaUnited States
-
Novartis PharmaceuticalsRecruitingMyeloid Leukemia, Philadelphia PositiveKorea, Republic of, Germany, France, United States, Greece, Hungary, Italy, Japan, Poland, Russian Federation, Thailand, Turkey, China, Netherlands
-
University of JenaNovartis Pharmaceuticals; Ludwig-Maximilians - University of MunichActive, not recruiting
-
Novartis PharmaceuticalsActive, not recruiting
-
Augusta UniversityH. Jean Khoury Cure CML ConsortiumRecruitingLeukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, ChronicUnited States
-
Novartis PharmaceuticalsCompletedChronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaGermany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States